Fall Reporting with GLP-1 Receptor Agonists in Older Adults: A FDA Adverse Event Reporting System (FAERS) Disproportionality Analysis

Imagine the human body as a bustling city. In this city, there are delivery trucks (hormones) that tell your cells to open their doors and accept sugar for energy. One of the most popular delivery trucks is called GLP-1. Recently, scientists have built super-charged versions of this truck, called GLP-1 receptor agonists, to help people manage their blood sugar and even lose weight. These "super-trucks" are incredibly effective, but like any powerful vehicle, they come with a safety manual.

Now, think about the elderly population in this city. As people get older, their city streets can get a bit bumpier, and their balance might wobble. A "fall" in this context isn't just a stumble; it's a major event that can lead to broken bones, hospital stays, and a loss of independence. Doctors have long known that certain medications can make these falls more likely, often by making people dizzy or causing their blood pressure to drop suddenly when they stand up (like a sudden power outage in the city grid). But there's a nagging question: Do these new, popular weight-loss and diabetes drugs make older people fall more often, and if so, is it because of that sudden blood pressure drop, or is it something else entirely?

This is the mystery that a team of researchers set out to solve. They didn't run a new experiment with people; instead, they acted like giant digital detectives. They scoured a massive database called FAERS, which is essentially a giant "tip line" where doctors and patients report anything strange that happens after taking a medicine. They wanted to see if there was a pattern: Did older people report falling more often than younger people when taking these specific drugs? And if they did, was it just because they felt dizzy, or was there a different story?

The Detective Work: Sifting Through the Tip Line

The researchers focused on four of the most popular GLP-1 drugs: semaglutide, tirzepatide, liraglutide, and dulaglutide. They looked at nearly 187,000 reports submitted between 2010 and mid-2026. To make sure they were comparing apples to apples, they split the data into two groups: the "younger" crowd (under 65) and the "older" crowd (ages 65 to 84). They also had a special group of "oldest-old" folks (85 and up) to see if the pattern got even wilder with age.

Their main job was to count how many times "Fall" was reported compared to how many times "Dizziness," "Fainting" (Syncope), or "Low Blood Pressure when Standing" (Orthostatic Hypotension) were reported. They used a special math tool called a "Reporting Odds Ratio" (ROR). Think of this like a volume knob: if the knob is at 1, the reports are equal. If it's at 2, the older group is reporting that event twice as often as the younger group.

The Big Discovery: The Fall That Wasn't Dizziness

The results were like finding a giant, glowing neon sign in the data. The researchers found that falls were reported much more frequently by older adults compared to younger adults. The "volume knob" for falls was turned up to 2.75. This means that for every fall reported by a younger person, there were nearly three reported by an older person taking the same drug.

But here is the twist that makes this story so interesting: The usual suspects were innocent.

If these falls were happening because the drugs made people dizzy or caused their blood pressure to crash, the researchers would have seen a similar spike in reports of "Syncope" (fainting) or "Orthostatic Hypotension." But they didn't.

• Syncope (Fainting): The ratio was 0.96. This is basically a flat line. Older people weren't fainting any more often than younger people.
• Orthostatic Hypotension: The ratio was 1.36, which wasn't statistically significant enough to be considered a real signal.

This is a crucial distinction. It suggests that the falls aren't happening because the older adults are suddenly losing consciousness or their blood pressure is dropping like a stone. Instead, the falls seem to be happening for a different reason entirely.

The Age Factor: The Older You Get, The Louder the Signal

The researchers then broke down the older group even further, and the pattern got even more dramatic. It wasn't just that older people fell more; the risk seemed to climb steeply with every decade of age.

• For people aged 65–74, the fall signal was 2.30.
• For people aged 75–84, it jumped to 3.91.
• For the 85+ group, the signal skyrocketed to 7.13.

This means that in the oldest group, falls were reported more than seven times as often as in the younger group. Even after the researchers adjusted for other factors—like whether the patient had diabetes or was reporting for weight loss, and who wrote the report (a doctor or a regular person)—the signal remained strong. The adjusted number was still 2.34, confirming that age itself is a major factor.

What This Means (And What It Doesn't)

The researchers are careful to say that this study doesn't prove that these drugs cause falls. It's like seeing a lot of ice cream sales and a lot of shark attacks on the same day; it doesn't mean ice cream causes shark attacks, but it tells us to look closer. However, the fact that the signal is so strong, and that it happens without the usual "dizziness" symptoms, points to a new theory.

The authors suggest that the falls might be linked to non-hemodynamic factors. In plain English, this means the drugs might be causing muscle weakness, loss of balance, or making people feel frail, rather than just making them dizzy. Since GLP-1 drugs are famous for helping people lose weight quickly, it's possible that older adults are losing muscle mass along with fat, making them wobbly on their feet.

The study also looked at the specific drugs. The pattern held true for all four of them: semaglutide, tirzepatide, dulaglutide, and liraglutide. Dulaglutide showed the strongest signal, but the trend was consistent across the board.

The Bottom Line

This study acts as a giant "check engine" light for doctors and patients. It suggests that when older adults take these popular GLP-1 drugs, they might be at a higher risk of falling, but not because they are fainting or dizzy. The risk seems to grow significantly as people get older, especially past 85.

The researchers conclude that we need to look at these patients differently. Instead of just checking their blood pressure when they stand up, doctors might need to check their muscle strength, their balance, and how many other medications they are taking. While this study doesn't prove the drugs are dangerous, it strongly suggests that for older adults, the risk of falling is a real and growing concern that deserves a fresh look, separate from the usual dizziness warnings. It's a call to action to keep our city's older residents steady on their feet, even as they ride these powerful new delivery trucks.